We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
+6.71%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.5M
AUM Growth
+$956K
Cap. Flow
+$1.31M
Cap. Flow %
1.81%
Top 10 Hldgs %
68.94%
Holding
88
New
10
Increased
5
Reduced
17
Closed
17

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$3.65M
2
XOM icon
ExxonMobil
XOM
+$2.26M
3
VTLE
Vital Energy
VTLE
+$1.5M
4
VRNA
Verona Pharma
VRNA
+$1.21M
5
FANG icon
Diamondback Energy
FANG
+$811K

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$2.39M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$1.78M
3
ARWR icon
Arrowhead Research
ARWR
+$989K
4
LNTH icon
Lantheus
LNTH
+$852K
5
CF icon
CF Industries
CF
+$772K

Sector Composition

Rank Sector Weight
1 Healthcare 60.54%
2 Energy 29.19%
3 Technology 7.65%
4 Communication Services 1.77%
5 Industrials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STAA icon
1
STAAR Surgical
STAA
$1.14B
$15.7M 21.69%
222,800
-6,100
-3% -$522K
XOM icon
2
ExxonMobil
XOM
$628B
$7.12M 9.83%
81,600
+24,700
+43% +$2.26M
DVN icon
3
Devon Energy
DVN
$48.5B
$4.96M 6.85%
82,500
– –
KRYS icon
4
Krystal Biotech
KRYS
$9.64B
$4.06M 5.61%
58,300
-700
-1% -$50.6K
ARWR icon
5
Arrowhead Research
ARWR
$12.2B
$3.65M 5.04%
110,500
-24,500
-18% -$989K
AXSM icon
6
Axsome Therapeutics
AXSM
$11B
$3.26M 4.5%
+73,000
New +$3.65M
CVX icon
7
Chevron
CVX
$371B
$3.23M 4.46%
22,500
+3,000
+15% +$458K
ADTN icon
8
Adtran
ADTN
$641M
$2.94M 4.05%
150,000
– –
NVNO
9
enVVeno Medical
NVNO
$7.39M
$2.52M 3.48%
11,463
– –
CLSD
10
DELISTED
Clearside Biomedical
CLSD
$2.48M 3.43%
146,499
-6,048
-4% -$132K
VTLE
11
DELISTED
Vital Energy
VTLE
$2.13M 2.94%
33,900
+21,100
+165% +$1.5M
ARCT icon
12
Arcturus Therapeutics
ARCT
$178M
$1.78M 2.46%
120,400
-106,200
-47% -$1.78M
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.77M 2.44%
7,833
-500
-6% -$123K
VRNA
14
DELISTED
Verona Pharma
VRNA
$1.47M 2.02%
+143,500
New +$1.21M
ET icon
15
Energy Transfer Partners
ET
$70B
$1.41M 1.95%
127,800
– –
FANG icon
16
Diamondback Energy
FANG
$52.4B
$1.26M 1.75%
10,500
+6,500
+163% +$811K
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
$1.08M 1.49%
60,000
-5,000
-8% -$79.8K
INMB icon
18
INmune Bio
INMB
$50.5M
$937K 1.29%
151,100
-9,400
-6% -$82.5K
IKT icon
19
Inhibikase Therapeutics
IKT
$377M
$853K 1.18%
156,250
– –
ROKU icon
20
Roku
ROKU
$21.8B
$761K 1.05%
13,500
+7,900
+141% +$601K
AFMD
21
DELISTED
Affimed
AFMD
$636K 0.88%
30,880
– –
CMBM
22
DELISTED
Cambium Networks
CMBM
$582K 0.8%
+34,400
New +$617K
TMDX icon
23
Transmedics
TMDX
$2.64B
$522K 0.72%
+12,500
New +$544K
SSYS icon
24
Stratasys
SSYS
$778M
$504K 0.7%
35,000
-15,000
-30% -$267K
CSBR icon
25
Champions Oncology
CSBR
$73.6M
$469K 0.65%
62,500
– –
1
2 3 4

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, ACT Capital Management held 88 positions worth $72.5M, up 1.3% from $71.5M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

ACT Capital Management's Q3 2022 filing shows 10 new, 5 increased, 17 reduced and 17 closed positions. Its largest new stake was Axsome Therapeutics: 73,000 shares worth $3.26M. The largest sale was IDEAYA Biosciences, an estimated $2.39M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 67% a quarter earlier, followed by Energy and Technology.

  • ACT Capital Management's largest Q3 2022 buy was Axsome Therapeutics: 73,000 shares worth $3.26M.
  • ACT Capital Management added most to ExxonMobil in Q3 2022, an estimated $2.26M increase.
  • ACT Capital Management's biggest Q3 2022 reduction was Arcturus Therapeutics, cutting an estimated $1.78M.
  • ACT Capital Management fully exited IDEAYA Biosciences in Q3 2022, selling an estimated $2.39M.
  • ACT Capital Management's ten largest holdings make up 69% of its $72.5M portfolio in Q3 2022.
  • ACT Capital Management opened 10 new positions and closed 17 in Q3 2022.
  • ACT Capital Management's portfolio value rose 1.3% quarter-over-quarter to $72.5M.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.